



SAFETY DATA SHEET

Revision date: 18-Apr-2018

Version: 7.1

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Tigecycline for Injection

Trade Name: TYGACIL; TYZEL
Compound Number: WAY-156936; GAR-936
Synonyms: Tigecycline For Injection for intravenous use
Chemical Family: Tetracycline derivative

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Serious Eye Damage/Eye Irritation: Category 1
Skin Sensitization: Category 1
Reproductive Toxicity: Category 1A
Acute aquatic toxicity: Category 1
Chronic aquatic toxicity: Category 2

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

Label Elements

Signal Word: Danger
Hazard Statements: H317 - May cause an allergic skin reaction
H318 - Causes serious eye damage
H360D - May damage the unborn child
H400 - Very toxic to aquatic life
H411 - Toxic to aquatic life with long lasting effects
May form combustible dust concentrations in air

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 2 of 11
Version: 7.1

Precautionary Statements:

- P202 - Do not handle until all safety precautions have been read and understood
- P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
- P280 - Wear protective gloves/protective clothing/eye protection/face protection
- P363 - Wash contaminated clothing before reuse
- P272 - Contaminated work clothing must not be allowed out of the workplace
- P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
- P310 - Immediately call a POISON CENTRE or doctor/physician
- P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
- P273 - Avoid release to the environment
- P391 - Collect spillage
- P405 - Store locked up
- P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**
Tigecycline	220620-09-7	Not Listed	Repr. 1A(H360D) Skin Sens.1(H317) Eye Dam.1(H318) Aquatic Acute 1 (H400) Aquatic Chronic 2 (H411)	30-35

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Lactose NF, monohydrate	64044-51-5	Not Listed	Not Listed	*

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 3 of 11
Version: 7.1

Additional Information: ** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 4 of 11
Version: 7.1

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³
Greece OEL - TWA	5 ppm
	7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm
	8 mg/m ³
Italy OEL - TWA	5 ppm
	8 mg/m ³
Japan - OELs - Ceilings	2 ppm
	3.0 mg/m ³
Latvia OEL - TWA	5 ppm
	8 mg/m ³
Lithuania OEL - TWA	5 ppm
	8 mg/m ³

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 5 of 11
Version: 7.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL -TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

SODIUM HYDROXIDE

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL -TWAs	2 mg/m ³

Tigecycline

Pfizer OEL TWA-8 Hr: 100 µg/m³, Sensitizer, Severe Eye Irritant

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 6 of 11
Version: 7.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Powder	Color:	Orange
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

HYDROCHLORIC ACID

No data available

SODIUM HYDROXIDE

No data available

Tigecycline

No data available Log P -0.09

Lactose NF, monohydrate

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 7 of 11
Version: 7.1

10. STABILITY AND REACTIVITY

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Long Term:

Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus. High doses of tetracyclines can cause a liver condition known as fatty liver. Individuals who suffer from high cholesterol, high triglycerides, or have alcoholic liver disease may be more susceptible. May produce kidney toxicity if kidney damage already exists (based on animal data).

Known Clinical Effects:

May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Symptoms of chronic exposure to tetracyclines include redness and swelling of the skin, rash, chills, tooth discoloration, yellowing of the skin and eyes, nausea, vomiting, diarrhea, stomach pain, and chest pain. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Wheezing, asthma, low or high blood pressure, dizziness, lung congestion, blood changes (leukocytosis, atypical lymphocytes, toxic granulation of granulocytes and thrombocytopenia purpura), convulsion or shock may also occur. Clinical use of this drug has caused inflammation of the pancreas (pancreatitis), liver effects, increased mortality. Photosensitivity has been reported in some individuals taking tetracyclines.

Acute Toxicity: (Species, Route, End Point, Dose)

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Tigecycline

Mouse (M) IV LD50 124 mg/kg
Mouse (F) IV LD50 98mg/kg
Rat IV LD50 106mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Tigecycline

Antigenicity- Passive cutaneous anaphylaxis Rat Negative
Antigenicity- Passive cutaneous anaphylaxis Mouse Negative
Skin Corrosivity (*In vitro*, RHE) Negative
Eye Irritation (*In vitro*, BCOP) Negative
Eye Irritation Rabbit Severe
Skin Sensitization - LLNA Mouse Positive

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Tigecycline

13 Week(s) Dog No route specified 1.5 mg/kg/day NOAEL Lymphoid tissue
26 Week(s) Rat Intravenous 6 mg/kg/day NOAEL No effects at maximum dose
13 Week(s) Rat No route specified 2 mg/kg/day NOAEL Lymphoid tissue

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 8 of 11
Version: 7.1

11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Tigecycline

Embryo / Fetal Development	Rabbit	Intravenous	4 mg/kg/day	NOAEL	No effects at maximum dose
Embryo / Fetal Development	Rat	No route specified	4 mg/kg/day	NOAEL	Maternal Toxicity, Fetotoxicity
Embryo / Fetal Development	Rabbit	No route specified	4 mg/kg/day	NOAEL	No effects at maximum dose
Peri-/Postnatal Development	Rat	Intravenous	12 mg/kg/day	NOAEL	No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vivo</i> Micronucleus	Rat	Negative

Tigecycline

<i>In Vitro</i> Chromosome Aberration	Chinese Hamster Ovary (CHO) cells	Negative
<i>In Vivo</i> Micronucleus	Mouse	Negative
<i>In Vitro</i> Forward Mutation Assay	Mouse Lymphoma	Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

IARC:

Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Toxic to aquatic organisms. May cause long term adverse effects in the aquatic environment.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Tigecycline

<i>Daphnia magna</i> (Water Flea)	OECD	EC50	48 Hours	2 mg/L
<i>Pimephales promelas</i> (Fathead Minnow)	OECD	LC50	72 Hours	0.26 mg/L
<i>Daphnia Magna</i> (Water Flea)	OECD	NOEC	21 Days	2.1 mg/L
Algal Growth Inhibition	OECD	EC50	72 Hours	1.65 mg/L
<i>Pimephales promelas</i> (Fathead Minnow)	OECD	NOEC	32 Days	22 ug/L
Midge	OECD	NOEC	28 Days	> 94 mg/L

Aquatic Toxicity Comments:

A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Tigecycline

Activated sludge	OECD	EC50	140 mg/L (hydrolyzed tygecycline)
Activated sludge	OECD	EC50	58 mg/L (unhydrolyzed tygecycline)

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 9 of 11
Version: 7.1

Partition Coefficient: (Method, pH, Endpoint, Value)

Tigecycline Log P -0.09

Mobility in Soil:

Sorption: (Method, Inoculum, Sorption Endpoint, Endpoint, Results)

Tigecycline

OECD Activated sludge Adsorption KOC 7610

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number:	UN 3077
UN proper shipping name:	Environmentally Hazardous Substance, Solid, n.o.s (Tigecycline)
Transport hazard class(es):	9
Packing group:	III
Environmental Hazard(s):	Marine Pollutant

5 kg/5L Exception:

UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not regulated as dangerous goods for transport by any mode:

* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances	5000 lb
and their Reportable Quantities:	2270 kg

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 10 of 11
Version: 7.1

15. REGULATORY INFORMATION

CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5
EU EINECS/ELINCS List	Schedule 6
	231-595-7
Lactose NF, monohydrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
SODIUM HYDROXIDE	
CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb
California Proposition 65	454 kg
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Present
EU EINECS/ELINCS List	Schedule 5
	Schedule 6
	215-185-5
Tigecycline	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage
Reproductive toxicity-Cat.1A; H360D - May damage the unborn child
Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 18-Apr-2018

SAFETY DATA SHEET

Material Name: Tigecycline for Injection
Revision date: 18-Apr-2018

Page 11 of 11
Version: 7.1

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet